论文部分内容阅读
目的探讨米非司酮单用及其与宫瘤消胶囊合用治疗子宫肌瘤的临床效果。方法选取2011年6月至2014年5月间收治的154例子宫肌瘤患者,按随机数字分组法分为治疗组和对照组。治疗组患者采用非司酮配合宫瘤消胶囊治疗,对照组患者采用米非司酮治疗,对比两组患者的治疗效果。结果治疗组患者治愈率(53.2%)和总有效率(92.2%)明显高于对照组患者(27.3%和(66.2%),差异均有统计学意义(均P<0.05)。两组患者治疗后,治疗组患者孕酮和雌二醇分别为(9.54±2.36)μg/L和(158.52±43.27)pmol/L,与对照组患者[分别为(16.42±3.21)μg/L和(220.43±45.36)pmol/L]对比,差异均有统计学意义(均P<0.05);两组患者经治疗后,治疗组患者子宫肌瘤体积和子宫体积分别为(33.25±12.42)m~3和(106.43±23.76)m~3,与对照组患者[分别为(45.74±15.52)m~3和(119.94±28.35)m~3]相比,差异均有统计学意义(P<0.05)。结论子宫肌瘤患者使用米非司酮配合宫瘤消胶囊治疗效果更显著,值得推广。
Objective To investigate the clinical efficacy of mifepristone alone and in combination with Gongyu Xiao capsule in the treatment of uterine fibroids. Methods 154 patients with uterine fibroids admitted from June 2011 to May 2014 were divided into treatment group and control group according to random number grouping method. Patients in the treatment group were treated with Nimomeong Capsules and Miriam Capsules. Patients in the control group were treated with mifepristone, and the treatment effect was compared between the two groups. Results The cure rate (53.2%) and total effective rate (92.2%) in the treatment group were significantly higher than those in the control group (27.3% vs 66.2%, both P <0.05) (9.54 ± 2.36) μg / L and (158.52 ± 43.27) pmol / L respectively in the treatment group compared with those in the control group [(16.42 ± 3.21) μg / L and (220.43 ± 45.36) pmol / L] (all P <0.05). After treatment, the uterine fibroids volume and uterine volume in the treatment group were (33.25 ± 12.42) m ~ 3 and 106.43 ± 23.76) m ~ 3, which were significantly different from those in the control group [(45.74 ± 15.52) m ~ 3 and (119.94 ± 28.35) m ~ 3, respectively] Patients with fibroids using mifepristone Miyao capsule treatment effect is more significant, it is worth promoting.